Thymosin alpha-1 has been used in hepatitis B and C, immunodeficiency and oncology trials for over 25 years with a consistently benign tolerability record: injection-site discomfort is the main finding and serious adverse events attributable to the drug are rare. Research-grade material is not the approved product.
What is reported
| Effect | Rate (sourced) | Detail | Source |
|---|
| Injection-site discomfort, redness | not quantified | Most common finding across trials. | Zadaxin product literature; trial reviews |
| Systemic adverse events | not quantified | Rates comparable to placebo in controlled trials; no consistent organ toxicity identified. | Camerini & Garaci 2015 (review) |
What is not known
- Research-grade identity and dose.
- Effects in autoimmune disease are theoretical and understudied.
Mechanism-based cautions
- Immunomodulator — theoretical concern in transplant recipients or active autoimmune disease.
Regulatory status: Approved as Zadaxin in more than 35 countries; not FDA-approved. Research-grade Tα1 is not approved.
References
- Camerini R, Garaci E. Historical review of thymosin α1 in infectious diseases. Expert Opinion on Biological Therapy, 2015.
Frequently asked
Is thymosin alpha-1 safe?
Among peptides on this site it has the longest and cleanest human record, in trials and approved use abroad. That record belongs to the pharmaceutical product, not to any research vial.
Thymosin Alpha-1 research profile